title: Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology.
abstract: The use of primary mammalian neurons derived from embryonic central nervous system tissue is limited by the fact that once terminally differentiated into mature neurons, the cells can no longer be propagated. Transformed neuronal-like cell lines can be used in vitro to overcome this limitation. However, several caveats exist when utilizing cells derived from malignant tumors. In this context, the popular SH-SY5Y neuroblastoma cell line and its use in in vitro systems is described. Originally derived from a metastatic bone tumor biopsy, SH-SY5Y (ATCC(®) CRL-2266™) cells are a subline of the parental line SK-N-SH (ATCC(®) HTB-11™). SK-N-SH were subcloned three times; first to SH-SY, then to SH-SY5, and finally to SH-SY5Y. SH-SY5Y were deposited to the ATCC(®) in 1970 by June L. Biedler.Three important characteristics of SH-SY5Y cells should be considered when using these cells in in vitro studies. First, cultures include both adherent and floating cells, both types of which are viable. Few studies address the biological significance of the adherent versus floating phenotypes, but most reported studies utilize adherent populations and discard the floating cells during media changes. Second, early studies by Biedler's group indicated that the parental differentiated SK-N-SH cells contained two morphologically distinct phenotypes: neuroblast-like cells and epithelial-like cells (Ross et al., J Nat Cancer Inst 71:741-747, 1983). These two phenotypes may correspond to the "N" and "S" types described in later studies in SH-SY5Y by Encinas et al. (J Neurochem 75:991-1003, 2000). Cells with neuroblast-like morphology are positive for tyrosine hydroxylase (TH) and dopamine-β-hydroxylase characteristic of catecholaminergic neurons, whereas the epithelial-like counterpart cells lacked these enzymatic activities (Ross et al., J Nat Cancer Inst 71:741-747, 1983). Third, SH-SY5Y cells can be differentiated to a more mature neuron-like phenotype that is characterized by neuronal markers. There are several methods to differentiate SH-SY5Y cells and are mentioned below. Retinoic acid is the most commonly used means for differentiation and will be addressed in detail.
authors: Department of Neuroscience, Temple University School of Medicine, Philadelphia, PA, USA.
authors: Jane
authors: J
authors: Kovalevich
authors: Dianne
authors: D
authors: Langford
mesh_terms: D018929:Cell Culture Techniques; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D015925:Cryopreservation; D006801:Humans; D009446:Neurobiology / Q000379:methods*; D009447:Neuroblastoma / Q000473:pathology*
references: Cell Growth Differ. 1990 Feb;1(2):79-85
references: 1964795
references: J Neurochem. 2007 Sep;102(6):1941-1952
references: 17540009
references: Brain Res. 1987 Jun;430(2):235-42
references: 3607514
references: J Biol Chem. 1999 Dec 24;274(52):37046-52
references: 10601262
references: J Neurochem. 2008 Aug;106(4):1669-80
references: 18631215
references: Br J Pharmacol. 2005 Dec;146(8):1087-95
references: 16230999
references: J Biol Chem. 2002 Jul 12;277(28):25297-304
references: 12000752
references: Neurosci Lett. 1992 Oct 12;145(2):201-4
references: 1465217
references: J Neurochem. 1993 Jan;60(1):289-98
references: 8417148
references: Cell Differ. 1984 Jun;14(2):135-44
references: 6467378
references: J Neurochem. 2000 Sep;75(3):991-1003
references: 10936180
references: FASEB J. 1996 Jul;10(9):1031-9
references: 8801164
references: Anal Biochem. 2001 Nov 15;298(2):163-9
references: 11757502
references: Brain Res. 1984 Jun 8;302(2):323-34
references: 6329460
references: Neurotox Res. 2004;5(8):579-98
references: 15111235
references: Mol Cell Neurosci. 1993 Feb;4(1):1-12
references: 19912902
references: J Neurochem. 1996 Jul;67(1):131-7
references: 8666983
references: J Neurochem. 1991 May;56(5):1810-5
references: 1901596
references: Neurosci Lett. 2008 Oct 10;443(3):199-203
references: 18691633
references: J Neurosci Res. 1999 Nov 1;58(3):426-35
references: 10518116
references: J Neurophysiol. 1998 Feb;79(2):648-58
references: 9463428
references: J Cell Physiol. 1986 Aug;128(2):285-92
references: 3090056
references: Science. 1993 Jun 11;260(5114):1661-4
references: 8389057
references: Chin Med J (Engl). 2010 Apr 20;123(8):1086-92
references: 20497720
references: Neurotoxicology. 2009 Jan;30(1):127-35
references: 19056420
references: Int J Cancer. 1981 Nov 15;28(5):583-9
references: 7309295
references: Brain Res. 2010 Jun 14;1337:85-94
references: 20380819
references: Oncogene. 2008 May 22;27(23):3339-44
references: 18212744
references: Int J Dev Neurosci. 2009 Apr;27(2):135-47
references: 19111604
references: J Cell Biochem. 2006 Jan 1;97(1):198-206
references: 16200638
references: Cancer Res. 1978 Nov;38(11 Pt 1):3751-7
references: 29704
references: J Neural Transm Suppl. 2007;(72):17-28
references: 17982873
references: J Natl Cancer Inst. 1983 Oct;71(4):741-7
references: 6137586
references: J Neurooncol. 1997 Jan;31(1-2):65-83
references: 9049832
references: J Alzheimers Dis. 2010;20(4):1069-82
references: 20413890
references: Neurochem Int. 2004 Mar;44(4):231-42
references: 14602086